Metabolic disease and adverse events from immune checkpoint inhibitors. Issue 6 (10th May 2021)

• Record Type: Journal Article
• Authors: Leiter, Amanda; Carroll, Emily; De Alwis, Sonia; Brooks, Danielle; Ben Shimol, Jennifer; Eisenberg, Elliot; Wisnivesky, Juan P; Galsky, Matthew D; Jane Gallagher, Emily
• Is Part Of: European journal of endocrinology. Volume 184:Issue 6(2021)
• Page Start: 857
• Page End: 865
• Publication Date: 2021-05-10
• Subjects: Endocrinology -- Periodicals; 616.4005
• DOI: 10.1530/EJE-20-1362
• Languages: English
• ISSNs: 0804-4643

Abstract

Abstract : Objective: Obese and overweight body mass index (BMI) categories have been associated with increased immune-related adverse events (irAEs) in patients with cancer receiving immune checkpoint inhibitors (ICIs); however, the impact of being overweight in conjunction with related metabolic syndrome-associated factors on irAEs have not been investigated. We aimed to evaluate the impact of overweight and obese BMI according to metabolic disease burden on the development of irAEs. Design and methods: We conducted a retrospective observational study of patients receiving ICIs at a cancer center. Our main study outcome was development of ≥grade 2 (moderate) irAEs. Our main predictor was weight/metabolic disease risk category: (1) normal weight (BMI 18.5–24.9 kg/m 2 )/low metabolic risk (<2 metabolic diseases (diabetes, dyslipidemia, hypertension)), (2) normal weight/high metabolic risk (≥2 metabolic diseases), (3) overweight (BMI ≥ 25 kg/m 2 )/low metabolic risk, and (4) overweight/high metabolic risk. Results: Of 411 patients in our cohort, 374 were eligible for analysis. Overall, 111 (30%) patients developed ≥grade 2 irAEs. In Cox analysis, overweight/low metabolic risk was significantly associated with ≥grade 2 irAEs (hazard ratio (HR): 2.0, 95% confidence interval (95% CI): 1.2–3.4) when compared to normal weight/low metabolic risk, while overweight/high metabolic risk (HR: 1.3, 95% CI: 0.7–2.2) and normal weight/high metabolic risk (HR: 1.5, 95% CI: 0.7–3.0) were not. Conclusions: Overweight patients with fewer metabolic comorbidities were at increased risk for irAEs. This study provides an important insight that BMI should be evaluated in the context of associated metabolic comorbidities in assessing risk of irAE development and ICI immune response.